Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-A18 pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer
jRCT2080225094Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Chemoradiotherapy + pembrolizumab with Chemoradiotherapy + placebo for pembrolizumab (2 arms). Started Feb 2020; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2080225094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225094.